PPARα is down-regulated following liver transplantation in mice

Journal of Hepatology

Volumn 56, Issue 3, 2012, Pages 586-594

  Nakagawa, Kan ^a,b   Tanaka, Naoki ^a,b   Morita, Miwa ^c   Sugioka, Atsushi ^c   Miyagawa, Shin Ichi ^b   Gonzalez, Frank J ^d   Aoyama, Toshifumi ^a  

^a SHINSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Early graft dysfunction; Liver transplantation; Mitochondrial oxidation; Oxidative stress; PPAR

Indexed keywords

CLOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FATTY ACID OXIDATION; LIVER CELL DAMAGE; LIVER TRANSPLANTATION; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OXIDATIVE STRESS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ACETYL COENZYME A; ADAPTATION, PHYSIOLOGICAL; ANIMALS; CITRIC ACID CYCLE; DOWN-REGULATION; LIVER TRANSPLANTATION; MALE; MICE; MICE, 129 STRAIN; MICE, MUTANT STRAINS; MITOCHONDRIA; OXIDATIVE STRESS; PHENOTYPE; PPAR ALPHA; PRIMARY GRAFT DYSFUNCTION;

EID: 84857358125     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.08.021     Document Type: Article

References (47)

1. C.L. Berg, D.E. Steffick, E.B. Edwards, J.K. Heimbach, J.C. Magee, and W.K. Washburn Liver and intestine transplantation in the United States 1998-2007 Am J Transplant 9 2009 907 931
2. A. Mehrabi, H. Fonouni, S.A. Müller, and J. Schmidt Current concepts in transplant surgery: liver transplantation today Langenbecks Arch Surg 393 2008 245 260
3. Nissen NN, Colquhoun SD. Graft failure: etiology, recognition, and treatment. In: Busuttil RW, Klintmalm GB, editors. Transplantation of the liver. Philadelphia: Elsevier Saunders; 2005. p. 915-928.
4. W.A. Marsman, R.H. Wiesner, L. Rodriguez, K.P. Batts, M.K. Porayko, and J.E. Hay Use of fatty donor liver is associated with diminished early patient and graft survival Transplantation 62 1996 1246 1251
5. A. Burke, and M.R. Lucey Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation Am J Transplant 4 2004 686 693
6. K.D. Chavin, R.N. Fiorini, S. Shafizadeh, G. Cheng, C. Wan, and Z. Evans Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation Am J Transplant 4 2004 1440 1447
7. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 1999 649 688
8. T. Aoyama, J.M. Peters, N. Iritani, T. Nakajima, K. Furihata, and T. Hashimoto Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα) J Biol Chem 273 1998 5678 5684
9. K. Watanabe, H. Fujii, T. Takahashi, M. Kodama, Y. Aizawa, and Y. Ohta Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α-associated with age-dependent cardiac toxicity J Biol Chem 275 2000 22293 22299
10. Y. Harano, K. Yasui, T. Toyama, T. Nakajima, H. Mitsuyoshi, and M. Mimani Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver Liver Int 26 2006 613 620
11. T. Nakajima, N. Tanaka, H. Kanbe, A. Hara, Y. Kamijo, and X. Zhang Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice. a novel peroxisome proliferator-activated receptor α-independent mechanism Mol Pharmacol 75 2009 782 792
12. S. Kersten, J. Seydoux, J.M. Peters, F.J. Gonzalez, B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting J Clin Invest 103 1999 1489 1498
13. G. Chinetti, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm Res 49 2000 497 505
14. T. Nakajima, Y. Kamijo, N. Tanaka, E. Sugiyama, E. Tanaka, and K. Kiyosawa Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage Hepatology 40 2004 972 980
15. J.D. Browning, and J.D. Horton Molecular mediators of hepatic steatosis and liver injury J Clin Invest 114 2004 147 152
16. S. Mandard, M. Müller, and S. Kersten Peroxisome proliferator-activated receptor α target genes Cell Mol Life Sci 61 2004 393 416
17. A.A. Nanji, A.J. Dannenberg, K. Jokelainen, and N.M. Bass Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-α (PPARα)-regulated genes and is ameliorated by PPARα activation J Pharmacol Exp Ther 310 2004 417 424
18. H. Glosli, O.A. Gudbrandsen, A.J. Mullen, B. Halvorsen, T.H. Røst, and H. Wergedahl Down-regulated expression of PPARα target genes;reduced fatty acid oxidation and altered fatty acid composition in the liver of mice transgenic for hTNFα Biochim Biophys Acta 1734 2005 235 246
19. P. Razeghi, M.E. Wang, K.A. Youker, L. Golfman, S. Stepkowski, and H. Taegtmeyer Lack of NF-κB1 (p105/p50) attenuates unloading-induced downregulation of PPARα and PPARα-regulated gene expression in rodent heart Cardiovasc Res 74 2007 133 139
20. M.S. Kim, T.R. Sweeney, J.K. Shigenaga, L.G. Chui, A. Moser, and C. Grunfeld Tumor necrosis factor and interleukin 1 decrease RXRα, PPARα, PPARγ, LXRα, and the coactivators SRC-1,PGC-1α, and PGC-1 β in liver cells Metabolism 56 2007 267 279
21. C.P. Baines, R.A. Kaiser, N.H. Purcell, N.S. Blair, H. Osinska, and M.A. Hambleton Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death Nature 434 2005 658 662
22. Y. Tsujimoto, T. Nakagawa, and S. Shimizu Mitochondrial membrane permeability transition and cell death Biochim Biophys Acta 1757 2006 1297 1300
23. N. Sambandam, D. Morabito, C. Wagg, B.N. Finck, D.P. Kelly, and G.D. Lopaschuk Chronic activation of PPARα is detrimental to cardiac recovery after ischemia Am J Physiol Heart Circ Physiol 290 2006 H87 95
24. A.J. Belanger, Z. Luo, K.A. Vincent, G.Y. Akita, S.H. Cheng, and R.J. Gregory Hypoxia-inducible factor 1 mediates hypoxia-induced cardiomyocyte lipid accumulation by reducing the DNA binding activity of peroxisome proliferator-activated receptor α/retinoid X receptor Biochem Biophys Res Commun 364 2007 567 572
25. W. Okiyama, N. Tanaka, T. Nakajima, E. Tanaka, K. Kiyosawa, and F.J. Gonzalez Polyenephosphatidylcholine prevents alcoholic liver disease in PPARα-null mice through attenuation of increases in oxidative stress J Hepatol 50 2009 1236 1246
26. O. Dewald, S. Sharma, J. Adrogue, R. Salazar, G.D. Duerr, and J.D. Crapo Downregulation of peroxisome proliferator-activated receptor-α gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity Circulation 112 2005 407 415
27. T. Okaya, and A.B. Lentsch Peroxisome proliferator-activated receptor-α regulates postischemic liver injury Am J Physiol Gastrointest Liver Physiol 286 2004 G606 G612
28. N.C. Teoh, J. Williams, J. Hartley, J. Yu, R.S. McCuskey, and G.C. Farrell Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14, 643 protects murine fatty liver against ischemia-reperfusion injury Hepatology 51 2010 996 1006
29. H.E. Ramsey, C.G. Da Silva, C.R. Longo, E. Csizmadia, P. Studer, and V.I. Patel A20 protects mice from lethal liver ischemia/reperfusion injury by increasing peroxisome proliferator-activated receptor-alpha expression Liver Transpl 15 2009 1613 1621
30. M. Massip-Salcedo, M.A. Zaouali, S. Padrissa-Altés, A. Casillas-Ramirez, J. Rodés, and J. Roselló-Catafau Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion Hepatology 47 2008 461 472
31. S.G. Qian, J.J. Fung, A.V. Demetris, S.T. Ildstad, and T.E. Starzl Orthotopic liver transplantation in the mouse Transplantation 52 1991 562 564
32. J.H. Birsner, C. Wan, G. Cheng, Z.P. Evans, C.C. Polito, and R.N. Fiorini Steatotic liver transplantation in the mouse: a model of primary nonfunction J Surg Res 120 2004 97 101
33. W. Li, L. Lu, Z. Wang, L. Wang, J.J. Fung, and A.W. Thomson Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance J Immunol 166 2001 5619 5628
34. F. Fu, N.L. Thai, Y. Li, L. Lu, A.W. Thomson, and J.J. Fung Second-set rejection of mouse liver allografts is dependent on radiation-sensitive nonparenchymal cells of graft bone marrow origin Transplantation 61 1996 1228 1233
35. A. Sugioka, M. Morita, T. Kato, S. Hoshimoto, J. Fujita, and Z. Morise FK 506 inhibits tolerance induction in mice liver transplantation Transplant Proc 37 2005 146 147
36. S. Qian, Z. Wang, Y. Lee, Y. Chiang, C. Bonham, and J. Fung Transplant Proc 33 2001 226
37. A. Sugioka, M. Morita, J. Fujita, A. Hasumi, and T. Shiroishi Graft acceptance and tolerance induction in mouse liver transplantation using wild mice Transplant Proc 33 2001 137 139
38. L. Conzelmann, P. Schemmer, Z. Zhong, O. Smutney, H. Bunzendahl, and R. Thurman Orthotopic liver transplantation in knockout mice. is TNFalpha involved in early graft injury and regeneration? Transplant Proc 34 2002 2299 2300
39. + regulatory T cells in mouse hepatic allograft tolerance Liver Transpl 12 2006 1112 1118
40. M. Morita, M. Fujino, G. Jiang, Y. Kitazawa, L. Xie, and M. Azuma PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft Am J Transplant 10 2010 40 46
41. V.E. de Meijer, B.T. Kalish, M. Puder, and J.N. Ijzermans Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection Br J Surg 97 2010 1331 1339
42. L. McCormack, P. Dutkowski, A.M. El-Badry, and P.A. Clavien Liver transplantation using fatty livers: always feasible? J Hepatol 54 2011 1055 1062
43. P.A. Clavien, C.E. Oberkofler, D.A. Raptis, K. Lehmann, A. Rickenbacher, and A.M. El-Badry What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology 52 2010 715 729
44. H.M. Noujaim, J. de Goyet, E.F. Montero, C.M. Ribeiro, V.L. Capellozzi, and F. Crescentini Expanding postmortem donor pool using steatotic liver grafts: a new look Transplantation 87 2009 919 925
45. N. Tanaka, K. Sano, A. Horiuchi, E. Tanaka, K. Kiyosawa, and T. Aoyama Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis J Clin Gastroenterol 42 2008 413 418
46. N. Tanaka, X. Zhang, E. Sugiyama, H. Kono, A. Horiuchi, and T. Nakajima Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice Biochem Pharmacol 80 2010 1601 1612
47. N. Tanaka, K. Moriya, K. Kiyosawa, K. Koike, F.J. Gonzalez, and T. Aoyama PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice J Clin Invest 118 2008 683 694